![\"\"](\"https:\/\/static.stocktitan.net\/img\/icons\/Google_News_icon.svg\"){kind=icon}
<\/p>\n
\n
\n
<\/p>\n
<\/p>\n
\n
\n See more from StockTitan in Google Search and AI answers.
\n Adds StockTitan as a preferred source \u00b7 opens Google
\n <\/p>\n
\n
\n
\n
<\/p>\n
07\/07\/2026 – 01:00 AM<\/p>\n
Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib\/IIa Brainshuttle AD study and design of Phase III PrevenTRON study in preclinical Alzheimer\u2019s<\/p>\n
New data on Roche\u2019s CE mark Elecsys pTau217 blood test will be presented on its use for Alzheimer’s diagnosis in both primary and secondary care<\/p>\n
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– \n\u201cWe aim to bring together advanced diagnostics and transformative medicines, with the goal of benefitting many Alzheimer’s patients through earlier detection and intervention,\u201d said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. \u201cOur presentations at AAIC will feature data from our expanding Alzheimer\u2019s disease portfolio, including investigational trontinemab, neuroinflammatory approaches and blood-based diagnostics.\u201d<\/p>\n \n\u201cWith the approval of Elecsys pTau217, our third Alzheimer\u2019s blood test, across both primary and secondary care, we are making timely and definitive diagnosis more accessible than ever before,\u201d said Matt Sause, CEO of Roche Diagnostics. \u201cFor too long, this has been out of reach for the vast majority of patients. As a result, millions have been left without the answers, care and support they need. That is now changing, as blood-based testing transforms the diagnosis of Alzheimer\u2019s disease.\u201d<\/p>\n \nPharmaceuticals<\/p>\n \nTrontinemab Featured Research Session<\/p>\n \nA 90-minute Featured Research Session will showcase five oral presentations focused on the latest progress in the development of trontinemab, an investigational BrainshuttleTM bispecific 2+1 amyloid-beta targeting monoclonal antibody. Presenters will share new long-term safety, amyloid removal and biomarker data from the Phase Ib\/IIa Brainshuttle AD open-label extension study. Modeling from this study has informed the dosing regimen for the ongoing Phase III TRONTIER 1 and 2 studies in early symptomatic Alzheimer\u2019s disease.<\/p>\n \nFor the first time, Genentech and Roche will also share the design of PrevenTRON, a Phase III study investigating trontinemab in preclinical Alzheimer\u2019s disease. PrevenTRON is planning to recruit cognitively unimpaired individuals at high risk of progression to symptomatic Alzheimer\u2019s, and investigators are using Roche\u2019s Elecsys pTau217 blood test to help identify potential study participants.<\/p>\n \nNLRP3 Inhibition Invited Perspectives Session<\/p>\n \nIn addition to targeting amyloid with trontinemab, Genentech and Roche are exploring multiple other investigational therapeutic approaches to tackle the complexity of neurodegenerative diseases. AAIC has invited Roche to present a Perspectives Session on NLRP3 inflammasome in Alzheimer\u2019s disease. Emerging preclinical and clinical data on the immunomodulatory effects of NLRP3 inhibition in neurodegenerative disorders such as Alzheimer\u2019s and Parkinson\u2019s disease will also be presented.<\/p>\n \nDiagnostics<\/p>\n \nRoche\u2019s Elecsys pTau217 blood test recently received CE mark certification as both a rule-in and rule-out test of amyloid pathology to aid in Alzheimer\u2019s disease diagnosis, and data will be presented evaluating the test\u2019s performance in primary and secondary care settings. In addition, new data will be presented for the approved Elecsys pTau181 blood test for ruling out Alzheimer\u2019s disease, which explores sample stability under different storage conditions and tests performance across large, diverse, cognitively impaired patient populations to support implementation of the test in routine clinical practice.<\/p>\n \nRoche is sponsoring a symposium \u201cClosing the Diagnostic Gap: Utilizing pTau217 for Scalable Alzheimer\u2019s Disease Diagnosis\u201d on Sunday, July 12 at 12:30-13:45 BST at the Crowne Plaza London Docklands Hotel. The symposium will discuss the evolving role of blood-based biomarkers in the early detection and diagnosis of Alzheimer\u2019s disease, including the potential of scalable blood testing approaches designed to help reduce diagnostic barriers, enable earlier identification of individuals at risk, and support broader access to disease-modifying therapies in clinical practice.<\/p>\n \nOverview of key presentations featuring Genentech and Roche pharmaceuticals and diagnostics:<\/p>\n \nAsset<\/p>\n \nTitle<\/p>\n \nAbstract \/ \nTrontinemab<\/p>\n \nLong-Term Safety and Amyloid Removal with Trontinemab: Interim Data from the Open-Label Extension of the Phase Ib\/IIa Brainshuttle\u2122 AD Study<\/p>\n \nOral Presentations (3-21-FRS-B)<\/p>\n \nTuesday, July 14<\/p>\n \n14:00\u201315:30 BST<\/p>\n \nRoom S8<\/p>\n \nInterim Long-Term Biomarker Results from the Trontinemab Open-Label Extension of the Phase Ib\/IIa Brainshuttle\u2122 AD Study<\/p>\n \nSimulation of Amyloid Clearance in Phase III Studies with Trontinemab in Early Symptomatic Alzheimer\u2019s Disease<\/p>\n \nEvidence Supporting Preclinical AD as an Optimal Stage for Intervention with Trontinemab<\/p>\n \nPrevenTRON: Rationale and Design of a Phase III Trial of Trontinemab in Cognitively Unimpaired Individuals with Biomarkers of Alzheimer\u2019s Disease at High Risk of Clinical Decline<\/p>\n \nNLRP3<\/p>\n \nThe Role of NLRP3 in Alzheimer’s Disease: Reverse Translational Data from GRADUATE Phase III Trials<\/p>\n \nOral Invited Talk (3-25-PER-C)<\/p>\n \nTuesday, July 14<\/p>\n \n14:00-15:30 BST<\/p>\n \nRoom N11A<\/p>\n \nInvestigating the Role of the NLRP3 Inflammasome in the Pathogenesis of Alzheimer\u2019s Disease<\/p>\n \nPoster Presentation (#0274)<\/p>\n \nTuesday, July 14<\/p>\n \n7:30\u201316:15 BST<\/p>\n \nExhibit Hall<\/p>\n \nClinical Insights<\/p>\n \nExternal Controls vs. Observed Placebo: How Close Can We Get? GRADUATE I and II Results<\/p>\n \nOral Presentation (2-15-FRS-A)<\/p>\n \nMonday, July 13<\/p>\n \n9:00\u201310:30 BST<\/p>\n \nRoom N10<\/p>\n \nTau Pathology Interferes with Amyloid Removal by Gantenerumab<\/p>\n \nOral Presentation (4-29-FRS-A)\u00a0<\/p>\n \nWednesday, July 15<\/p>\n \n14:00-15:30 BST<\/p>\n \nRoom Victoria 5\/6<\/p>\n \nPatients Living with Alzheimer\u2019s and their Caregivers<\/p>\n \nBurden and Support Needs of Informal Caregivers of People Living with Alzheimer\u2019s Disease in Three Countries<\/p>\n \nPoster Presentation (#0974)<\/p>\n \nTuesday, July 14<\/p>\n \n7:30\u201316:15 BST<\/p>\n \nExhibit Hall<\/p>\n \nMental Health Conditions in Spouses of People Living with Alzheimer’s Disease: A Longitudinal U.S. Claims Data Analysis<\/p>\n \nPoster Presentation (#0988)<\/p>\n \nWednesday, July 15<\/p>\n \n7:30\u201316:15 BST<\/p>\n \nExhibit Hall<\/p>\n \nClinical Trial Excellence<\/p>\n \nExpanding Clinical Trial Access to Underrepresented Populations in the U.S.: Findings from the Alzheimer\u2019s Disease Pre-Screener Study<\/p>\n \nPoster Presentation (#0174)<\/p>\n \nSunday, July 12<\/p>\n \n7:30\u201316:15 BST<\/p>\n \nExhibit Hall<\/p>\n \nA Low-Burden Cognitive Prescreening Protocol for Enhanced Diversity and Recruitment in Roche\u2019s Alzheimer\u2019s Disease Clinical Trials<\/p>\n \nPoster Presentation (#0038)<\/p>\n \nWednesday, July 15<\/p>\n \n7:30\u201316:15 BST<\/p>\n \nExhibit Hall<\/p>\n \nDiagnostics<\/p>\n \nRule-Out Performance of a Plasma pTau181 Immunoassay at Established Cutoffs in Subgroups Across a Large, Diverse, Cognitively Impaired Population<\/p>\n \nOral Presentation (4-29-FRS-A)<\/p>\n \nWednesday, July 15<\/p>\n \n14:00\u201315:30 BST<\/p>\n \nRoom Victoria 5\/6<\/p>\n \nEvaluating a Future In Vitro Diagnostic pTau217 Plasma Assay for the Detection of Amyloid Pathology in Primary and Secondary Care Settings<\/p>\n \nPoster Presentation (#1076)<\/p>\n \nSunday, July 12<\/p>\n \n7:30\u201316:15 BST<\/p>\n \nExhibit Hall<\/p>\n \nElecsys pTau181 Plasma Immunoassay Performance Against Centiloid-Based Amyloid Classification Across Clinical Stages<\/p>\n \nPoster Presentation (#1071)<\/p>\n \nSunday, July 12<\/p>\n \n7:30\u201316:15 BST<\/p>\n \nExhibit Hall<\/p>\n \nElecsys Cerebrospinal Fluid Biomarker Ratio Concordance with Amyloid-Positron Emission Tomography in a Chinese Population<\/p>\n \nPoster Presentation (#1070)<\/p>\n \nSunday, July 12<\/p>\n \n7:30\u201316:15 BST<\/p>\n \nExhibit Hall<\/p>\n \nSample Stability for a New pTau181 Plasma Immunoassay: Implications for Rule-Out Testing for Alzheimer\u2019s Disease in Routine Clinical Practice<\/p>\n \nPoster Presentation (#0476)<\/p>\n \nWednesday, July 15<\/p>\n \n7:30\u201316:15 BST<\/p>\n \nExhibit Hall<\/p>\n \nAbout Genentech and Roche in Alzheimer\u2019s<\/p>\n \nWith more than two decades of scientific research in Alzheimer\u2019s disease, Genentech and Roche are working towards a day when we can detect, diagnose, monitor and treat the condition earlier, so we can slow, stop or even prevent its progression.<\/p>\n \nToday, Genentech and Roche\u2019s Alzheimer\u2019s disease portfolio spans several investigational medicines for different targets, types and stages of the disease, including trontinemab, nivegacetor and RG6627. On the diagnostics side, it covers approved and investigational digital and blood-based tests and cerebrospinal fluid (CSF) assays, including Elecsys pTau181, pTau217 and ApoE4.<\/p>\n \nAddressing the global burden of Alzheimer\u2019s disease requires more than innovative tests and treatments. This is why we partner with clinicians, scientists, patient advocates, policymakers and health systems to help ensure that advances in Alzheimer\u2019s disease research translate into benefits for millions of people worldwide.<\/p>\n \nAbout Genentech<\/p>\n \nFounded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http:\/\/www.gene.com<\/a>.<\/p>\n
\nGenentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY<\/a>), announced today that it will present new data from its Alzheimer\u2019s disease portfolio at the Alzheimer\u2019s Association International Conference\u00ae 2026 (AAIC\u00ae) in London on July 12-15. These data demonstrate how Genentech and Roche are advancing the development of next-generation medicines and diagnostic tests, driven by a mission to slow, stop or even prevent the progression of Alzheimer\u2019s disease. In total, there are 18 oral and poster presentations. Highlights include five oral presentations as part of a trontinemab Featured Research Session, an oral Perspectives Session on neuroimmune targets such as NLRP3 for neurodegenerative diseases, and presentations on the use of Roche’s Elecsys\u00ae pTau217 and pTau181 blood tests to support Alzheimer\u2019s disease diagnosis.<\/p>\n
\n
Presentation Details<\/p>\n<\/p>\n